Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics
{{output}}
Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers. ... ...
